Gyre Therapeutics (GYRE) FCF Margin (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly FCF Margin of 13.42% for Q1 2026, up 1456.0% year-over-year from 0.86% in Q1 2025, and up 187.05% quarter-over-quarter from 15.42% in Q4 2025.
Powered by 
Analysis
Gyre Therapeutics (GYRE) FCF Margin (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported FCF Margin for 16 consecutive years, with 13.42% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin rose 1456.0% year-over-year to 13.42%; the TTM figure through Mar 2026 stood at 2.64% (up 1145.0% YoY), while the FY2025 annual figure was 0.15%, up 548.0% from the prior year.
- FCF Margin grew to 13.42% in Q1 2026 per GYRE's latest filing, from 15.42% in the prior quarter.
- Across five years, FCF Margin topped out at 41.67% in Q4 2022 and bottomed at 1517.63% in Q1 2022.
- Historically, FCF Margin has averaged 94.63% across 5 years, with a median of 7.0% in 2025.
- On a YoY basis, FCF Margin climbed as much as 155243 bps in 2023 and fell as far as 3786 bps in 2023.
- Gyre Therapeutics' FCF Margin stood at 41.67% in 2022, then tumbled by 91 bps to 3.82% in 2023, then sank by 353 bps to 9.66% in 2024, then sank by 60 bps to 15.42% in 2025, then soared by 187 bps to 13.42% in 2026.
- Business Quant data shows GYRE's FCF Margin at 13.42% in Q1 2026, 15.42% in Q4 2025, and 12.86% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Gyre Therapeutics | 691.38 Mn | 633.98 Mn | 26.90 Mn | -58.44% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -58.44% |
| Mar 31, 2026 | 13.42% |
| Dec 31, 2025 | -15.51% |
| Sep 30, 2025 | 44.66% |
| Jun 30, 2025 | -26.26% |
| Mar 31, 2025 | -1.14% |
| Dec 31, 2024 | -9.66% |
| Sep 30, 2024 | 4.05% |
| Jun 30, 2024 | -27.55% |
| Mar 31, 2024 | 9.76% |
| Dec 31, 2023 | 3.82% |
| Sep 30, 2023 | 17.50% |
| Jun 30, 2023 | 7.01% |
| Mar 31, 2023 | 34.80% |
| Dec 31, 2022 | 41.67% |
| Mar 31, 2022 | -1,517.63% |
| Dec 31, 2021 | -724.43% |
| Sep 30, 2021 | -960.94% |
| Jun 30, 2021 | -1,777.65% |
| Mar 31, 2021 | -1,660.26% |